nonnucleosid
revers
transcriptas
inhibitor
nnrti
key
compon
highli
activ
antiretrovir
therapi
treat
herein
present
synthesi
seri
uracil
deriv
bear
x
alkyl
substitu
novel
nnrti
compound
display
antihiv
activ
similar
nevirapin
sever
exhibit
activ
rt
mutant
strain
evalu
reveal
inhibitor
activ
nevirapineresist
monoand
disubstitut
rt
except
rt
thu
candid
compound
regard
potenti
lead
compound
wildtyp
viru
drugresist
form
third
decad
pandem
aid
underway
despit
extens
effort
scientist
across
globe
usa
alon
almost
million
patient
requir
antiretrovir
therapi
mani
develop
countri
number
order
magnitud
greater
date
antiretrovir
drug
approv
treatment
hiv
infect
use
highli
activ
antiretrovir
therapi
haart
compound
inhibit
hiv
replic
howev
use
often
hamper
toxic
sideeffect
long
period
therapi
well
loss
activ
face
emerg
drugresist
viru
strain
result
search
new
therapeut
minim
sideeffect
abil
retain
activ
drugresist
viru
strain
regard
critic
goal
medicin
chemist
antihiv
drug
compris
six
differ
class
compound
eight
nucleosid
nucleotid
revers
transcriptas
rt
inhibitor
nrti
four
nonnucleosid
rt
inhibitor
nnrti
ten
proteas
inhibitor
pi
one
integras
inhibitor
ini
one
fusion
inhibitor
fi
one
inhibitor
first
four
class
inhibitor
target
three
differ
viral
enzym
hivrt
hiv
proteas
hiv
integras
respect
nrti
nnrti
primari
compon
haart
one
area
ongo
research
laboratori
focus
design
synthesi
nnrti
compound
highli
specif
noncompetit
inhibitor
rt
key
enzym
involv
hiv
replic
sinc
five
nnrti
shown
fig
approv
fda
clinic
use
nevirapin
viramun
boehring
ingelheim
delavirdin
rescriptor
pharmacia
upjohn
efavirenz
sustiva
dupont
classifi
first
gener
nnrti
wherea
etravirin
intel
tibotec
rilpivirin
tibotec
consid
secondgener
nnrti
sinc
retain
activ
varieti
drugresist
viru
strain
nnrti
report
bind
nonnucleosid
inhibitor
bind
pocket
rt
nnibp
locat
palm
domain
subunit
distanc
approxim
enzym
catalyt
site
pocket
primarili
hydrophob
key
amino
acid
residu
involv
inhibitor
bind
includ
aromat
hydrophob
hydrophil
residu
rt
subunit
well
three
addit
amino
acid
subunit
one
major
limit
mani
nnrti
howev
rapid
emerg
variant
resist
drug
due
one
point
mutat
rt
bind
site
date
differ
structur
type
nnrti
design
describ
sever
current
regard
potenti
antihiv
drug
either
directli
follow
addit
structur
activ
relationship
sar
optim
lead
compound
one
scaffold
produc
strong
antivir
lead
activ
encompass
uracil
nucleobas
fig
uracil
analogu
variou
substitu
posit
exemplifi
scaffold
fig
proven
fruit
lead
develop
mani
analogu
exampl
deriv
shown
figur
shown
inhibit
hiv
replic
cell
cultur
nanomolar
concentr
howev
emerg
resist
viru
strain
hamper
clinic
use
recent
anoth
promis
nnrti
scaffold
fig
report
inhibitor
structur
type
found
highli
activ
wildtyp
clinic
signific
drugresist
form
class
compound
base
benzophenon
fragment
bridg
short
linker
orthomethylanilin
residu
sar
studi
reveal
substitu
two
metaposit
benzoyl
moieti
well
benzophenon
fragment
play
crucial
role
retain
antivir
activ
mutant
strain
thu
combin
lead
chimer
molecul
contain
uracil
residu
found
scaffold
well
benzophenon
fragment
found
scaffold
may
inhibit
rt
also
exhibit
strong
antivir
activ
toward
wildtyp
drugresist
viru
strain
fig
herein
report
synthesi
n
alkyl
uracil
deriv
initi
biolog
studi
describ
antivir
activ
synthesi
target
compound
carri
condens
equimolar
quantiti
trimethylsilyloxi
pyrimidin
alkan
start
bromid
prepar
accord
previous
describ
method
synthet
approach
key
advantag
reaction
result
n
substitut
uracil
product
format
n
product
observ
like
due
steric
hindranc
adjac
trimethylsilyl
group
block
approach
n
nitrogen
atom
known
condens
trimethylsilyl
pyrimidin
highli
reactiv
alkyl
agent
occur
facil
manner
aprot
solvent
mild
condit
high
yield
contrast
treatment
trimethylsilyloxi
pyrimidin
alkyl
agent
lower
reactiv
requir
elev
temperatur
condens
trimethylsilyl
uracil
deriv
allylbromid
benzylhalid
success
proce
presenc
catalyt
amount
iodin
heat
trimethylsilyloxi
pyrimidin
excess
alkyl
halid
lead
uracil
good
yield
previous
report
method
synthesi
phenoxi
ethyl
uracil
base
condens
trimethylsilyl
uracil
deriv
phenoxi
ethan
analog
rout
synthes
number
ethyl
x
ethyl
uracil
deriv
synthesi
scheme
accomplish
heat
trimethylsilyl
deriv
bromid
h
without
solvent
target
compound
obtain
yield
format
n
n
n
byproduct
observ
presenc
substitu
posit
pyrimidin
affect
regioselect
alkyl
exampl
condens
trimethylsilyloxi
molar
excess
lead
complex
mixtur
n
n
monoa
well
n
n
disubstitut
uracil
ratio
depend
upon
reaction
temperatur
result
altern
approach
synthesi
ethyl
need
thu
treatment
molar
excess
bromid
presenc
k
co
dmf
scheme
afford
yield
follow
separ
n
n
disubstitut
product
studi
influenc
bridg
carbonyl
group
antivir
properti
compound
reduc
analogu
compound
pursu
shown
scheme
treatment
nabh
presenc
naoh
result
hydroxyl
deriv
antihiv
properti
uracil
deriv
studi
human
tlymphocyt
cem
compound
compound
cell
cultur
infect
iiib
rod
doubl
mutant
rt
viru
strain
tabl
compound
found
inact
howev
compound
exhibit
notabl
antivir
activ
examin
structureact
relationship
sar
compound
becam
evid
ethyl
uracil
display
moder
level
activ
wherea
ethyl
counterpart
contain
bridg
carbonyl
linker
inhibit
hiv
replic
much
lower
compound
concentr
except
reduct
carbonyl
group
benzophenon
fragment
respect
alcohol
addit
methylen
group
linker
result
dramat
decreas
antivir
properti
substitu
r
appear
play
crucial
role
modul
antivir
activ
compound
benzophenon
bear
methyl
group
fluorin
atom
found
less
activ
counterpart
bear
chlorin
bromin
atom
vs
vs
increas
antivir
activ
obtain
insert
one
two
substitu
r
posit
compound
bear
two
methyl
group
exhibit
pronounc
activ
analog
possess
one
methyl
group
methyl
group
moreov
substitut
methyl
group
variou
halogen
signific
impact
antivir
activ
exemplifi
versu
ver
compound
also
evalu
drugresist
doubl
mutant
strain
bear
mutat
rt
mutat
result
pronounc
resist
nevirapin
much
lesser
extent
efavirenz
studi
benzophenon
found
inact
mutant
viru
tabl
howev
inhibit
replic
albeit
higher
compound
concentr
compound
also
retain
weak
level
activ
mutant
viru
strain
time
explain
differ
bind
affin
close
relat
benzophenon
toward
doubl
mutant
hiv
strain
howev
investig
current
underway
may
provid
addit
inform
may
shed
light
differ
level
activ
next
inhibitori
properti
uracil
deriv
rt
enzym
studi
standard
dnaand
rnadepend
dnapolymeras
assay
use
activ
dna
wildtyp
homodim
rt
poli
rc
oligo
dg
templateprim
heterodim
recombin
enzym
noteworthi
enzym
prepar
similar
activ
activ
dna
use
templateprim
assay
condit
describ
section
catalyz
incorpor
pmol
datp
per
second
per
lg
enzym
respect
nevirapin
efavirenz
use
refer
standard
tabl
preliminari
investig
mechan
action
perform
compound
dna
assay
shown
compound
act
noncompetit
manner
regard
dntp
substrat
fig
addit
uracil
deriv
retain
efficaci
enzymat
reaction
carri
presenc
heparin
ad
simultan
inhibitor
dntp
short
preincub
period
rt
activ
dna
fig
sinc
heparin
prevent
reiniti
polymer
reaction
indic
inhibitor
impact
elong
process
rt
reaction
effect
bind
enzym
nucleic
acid
inhibit
constant
k
reflect
affin
compound
rt
assess
use
dixon
plot
comparison
result
reveal
compound
display
similar
inhibitori
activ
activ
dna
poli
rc
oligo
dg
assay
correl
r
k
valu
test
compound
rt
assay
fig
moreov
correl
r
ec
replic
cell
cultur
k
rt
inhibit
use
respect
fig
examin
sar
compound
result
show
gener
also
notic
cell
cultur
system
ethyl
uracil
exhibit
greater
inhibit
hivrt
correspond
ethyl
counterpart
compound
differ
benzophenon
diphenylmethan
seri
especi
pronounc
compar
efficaci
compound
contrast
carbonyl
group
almost
influenc
activ
uracil
deriv
bear
methyl
group
r
r
posit
vs
nonetheless
consid
reduc
benzohydroxi
analogu
fail
inhibit
hivrt
benzophenon
carbonyl
fragment
appear
crucial
retent
activ
must
interact
enzym
fashion
comparison
antivir
activ
data
compound
bear
variou
substitu
r
led
surpris
result
one
hand
substitut
methyl
group
benzylphenoxi
ethyl
uracil
chlorin
bromin
almost
effect
potenc
compound
vs
howev
substitut
benzophenonecontain
compound
led
mark
enhanc
activ
inhibitor
bear
chlorin
bromin
r
posit
inhibit
rt
lower
concentr
comparison
counterpart
methyl
fluorin
substitu
vs
vs
notabl
result
agreement
antihiv
activ
observ
uracil
deriv
interestingli
sever
compound
show
decreas
inhibitori
activ
one
enzymat
assay
sinc
similar
structur
type
assay
discrep
could
attribut
poor
solubl
observ
halogen
compound
aqueou
media
particular
enzymat
reaction
condit
requir
assay
move
forward
sar
evalu
role
r
substitu
less
clear
one
hand
compound
lack
carbonyl
group
introduct
one
two
methyl
substitu
significantli
enhanc
inhibitori
activ
rt
vs
vs
hand
benzophenon
seri
correspond
inhibitor
display
activ
similar
unsubstitut
counterpart
vs
vs
observ
disagr
activ
compound
infect
cell
cultur
correl
found
pair
benzophenon
assay
activ
dna
assay
poli
rc
oligo
dg
assay
case
discrep
could
attribut
two
effect
greater
affin
substitut
benzophenon
enzym
andor
lower
solubl
compound
bear
halogen
substitu
next
order
fulli
understand
activ
benzophenon
drugresist
hiv
strain
well
verifi
reason
poor
level
activ
compound
rt
doubl
mutant
viru
panel
rt
bear
one
two
clinic
signific
mutat
confer
resist
viru
nnrti
construct
base
result
previous
highlight
antivir
studi
two
structurallyrel
benzophenon
select
studi
regard
compound
exhibit
highest
activ
wildtyp
viru
exhibit
quit
differ
level
activ
toward
doubl
mutant
strain
tabl
benzophenon
retain
activ
hivrt
form
except
tabl
although
absolut
k
valu
closer
nevirapin
resist
suscept
profil
compound
toward
hivrt
mutant
form
close
resembl
profil
efavirenz
exampl
nevirapin
efavirenz
exhibit
lower
activ
respect
toward
rt
mutant
compar
wildtyp
enzym
wherea
benzophenon
retain
almost
full
activ
exhibit
minor
degre
resist
respect
similarli
common
drugresist
hivrt
form
inhibitori
activ
nevirapin
lower
toward
wtrt
wherea
activ
efavirenz
studi
benzophenon
lower
respect
compound
prove
inact
rt
efavirenz
retain
activ
contrast
nevirapin
benzophenon
retain
partial
activ
form
rt
case
decreas
lower
efavirenz
rt
mutant
compound
inhibit
polymeras
less
effect
compar
decreas
nevirapin
efavirenz
respect
case
mutant
rt
activ
benzophenon
lower
wildtyp
enzym
compound
exhibit
lower
activ
nevirapin
efavirenz
less
activ
respect
interestingli
benzophenon
display
even
higher
inhibitori
activ
toward
mutant
rt
form
exhibit
somewhat
lower
activ
close
line
efavirenz
decreas
sharp
contrast
nevirapin
decreas
lastli
benzophenon
well
efavirenz
exhibit
lower
efficaci
toward
doubl
mutant
rt
compar
lower
inhibitori
activ
nevirapin
thu
data
obtain
highli
encourag
appear
point
resist
suscept
profil
synthes
benzophenon
closer
efavirenz
nevirapin
moreov
resist
index
compound
mutant
rt
compar
efavirenz
even
lower
mutant
although
mutant
efavirenz
potent
data
directli
support
result
antivir
activ
studi
reveal
differ
resist
suscept
profil
structurallyrel
benzophenon
possibl
differ
due
differ
solubl
compound
aqueou
media
rather
differ
mode
interact
mutant
hivrt
regard
note
dmso
use
rt
poli
rc
oligo
dg
experi
wherea
cell
cultur
contain
dmso
test
possibl
determin
solubl
sever
compound
dmso
solut
use
rt
activ
assay
use
cell
cultur
experi
uv
spectroscopi
found
maximum
concentr
compound
bear
halogen
tabl
assum
resist
index
compound
strain
shown
benzophenon
display
antivir
activ
strain
micromolar
concentr
rang
tend
precipit
inde
case
next
gener
benzophenon
design
enhanc
solubl
characterist
may
lead
obtain
effect
antiretrovir
agent
activ
varieti
drugresist
viral
strain
herein
describ
synthesi
sar
biolog
evalu
seri
potenti
nnrti
antihiv
agent
sever
uracil
deriv
exhibit
potent
antivir
activ
infect
cell
cultur
effect
inhibit
recombin
hivrt
notabl
compound
exhibit
toxic
cell
cultur
thu
high
select
indic
two
uracil
deriv
effect
inhibit
sever
mutant
rt
also
partial
retain
antivir
activ
sever
drugresist
hiv
strain
despit
encourag
result
poor
solubl
compound
hinder
true
assess
potenti
biolog
activ
although
activ
level
compound
toward
wildtyp
viru
rt
similar
nevirapin
close
resembl
activ
profil
efavirenz
retain
inhibitori
activ
toward
mutant
rt
form
resist
nevirapin
given
promis
potent
antivir
activ
exhibit
compound
clear
benzophenonelink
uracil
scaffold
excel
lead
develop
addit
compound
result
current
effort
underway
improv
solubl
insolubl
compound
order
design
effect
antihiv
drug
result
report
elsewher
becom
avail
activ
dna
purchas
ge
healthcar
littl
chalfont
uk
oligonucleotid
obtain
lytech
moscow
russia
p
datp
cimmol
h
dgtp
izotop
moscow
russia
moravek
biochem
brea
ca
respect
nintaagaros
resin
rosetta
escherichia
coli
strain
novagen
madison
wi
reagent
highest
grade
obtain
sigma
st
loui
mi
enzym
purchas
sybenzym
novosibirsk
russia
fermenta
vilnu
lithuania
chemic
obtain
commerci
sourc
use
without
purif
unless
otherwis
note
anhydr
dmf
isopropanol
ethylen
glycol
purchas
sigmaaldrich
co
anhydr
aceton
ch
cl
ethyl
acet
obtain
distil
p
melt
point
measur
meltemp
pro
apparatu
laboratori
devic
inc
uncorrect
h
c
nmr
spectra
regist
varian
mercuri
bruker
oper
mhz
h
mhz
c
respect
tetramethylsilan
tm
use
intern
standard
ppm
spin
multipl
indic
symbol
singlet
doublet
dd
doublet
doublet
triplet
q
quartet
multiplet
br
broad
reaction
monitor
thinlay
chromatographi
tlc
use
mm
silica
gel
precoat
plate
mass
spectra
record
john
hopkin
mass
spectrometri
facil
baltimor
md
xray
structur
analysi
perform
bruker
smart
difractomet
data
analyz
shelx
program
complet
structur
data
report
separ
yield
refer
chromatograph
hplc
spectroscop
h
c
nmr
homogen
materi
puriti
compound
verifi
use
hplc
compound
verifi
pure
minor
impur
uracil
briefli
compound
dissolv
dmso
purifi
use
nucleosil
mm
column
gilson
chromatograph
franc
suppli
digit
gilson
gsioc
control
uv
detector
vari
wavelength
compound
purifi
use
follow
two
protocol
gener
procedur
compound
trimethylsilyloxi
pyrimidin
prepar
uracil
thymin
mmol
reflux
excess
hmd
incub
bromid
mmol
h
kept
overnight
room
temperatur
result
product
treat
etoac
ml
isopropanol
ml
mixtur
kept
room
temperatur
min
evapor
result
residu
recrystal
twice
isopropanol
mixtur
isopropanoldmf
methodolog
antihiv
assay
cell
cultur
follow
viru
stock
titrat
cell
express
cell
cultur
infect
dose
ccid
cell
suspend
cultur
medium
cellsml
infect
hiv
multipl
infect
immedi
viral
infect
cell
suspens
place
well
flatbottom
microtit
tray
contain
variou
concentr
test
compound
test
compound
dissolv
dmso
mm
higher
day
incub
number
viabl
cell
determin
use
bromid
mtt
method
select
character
mutant
viru
strain
perform
previous
plasmid
encod
revers
transcriptas
rt
obtain
previous
report
plasmid
encod
rt
one
two
amino
acid
residu
substitut
construct
amplifi
gene
two
fragment
use
oligonucleotid
list
tabl
head
tail
pcrproduct
mix
togeth
absenc
oligo
addit
amplif
cycl
perform
order
obtain
fulllength
gene
result
product
digest
xhoi
xbai
restrict
endonucleas
ligat
pbrphr
vector
rt
gene
contain
mutat
insert
pbrphr
vector
mutant
gene
subclon
wildtyp
mutant
rt
express
e
coli
rosetta
strain
purifi
nintaagaros
resin
describ
earlier
hcv
rna
polymeras
rt
assay
use
activ
dna
perform
follow
standard
reaction
mixtur
contain
lg
activ
dna
lg
rt
lm
datp
lm
dctp
dgtp
dttp
lci
p
datp
trishcl
buffer
mm
ph
contain
also
mm
mgcl
kcl
rt
assay
use
poli
rc
oligo
dg
templateprim
complex
perform
follow
reaction
mixtur
contain
mm
poli
rc
oligo
dg
lg
rt
lm
radiolabel
h
dgtp
lci
lg
bsa
mm
trishcl
ph
supplement
mm
dtt
mm
mgcl
mm
nacl
glycerol
test
compound
dissolv
dmso
ad
assay
final
dmso
concentr
reaction
mixtur
incub
minut
appli
onto
whatman
filter
dri
air
filter
wash
twice
trichloracet
acid
twice
trichloracet
acid
ethanol
dri
air
radioact
measur
cherenkov
method
altern
ml
icecold
tca
na
p
ad
reaction
mixtur
incub
termin
polymer
reaction
acidinsolubl
precipit
radiolabel
dna
captur
onto
whatman
glass
fiber
filter
type
gfc
ge
healthcar
uk
limit
buckinghamshir
uk
wash
tca
ethanol
remov
free
radiolabel
dntp
radioact
determin
perkin
elmer
tricarb
tr
liquid
scintil
counter
